Citadel Advisors’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.22M | Sell |
17,100
-3,000
| -15% | -$205K | ﹤0.01% | 7222 |
|
|
2025
Q4 | $1.19M | Buy |
20,100
+10,100
| +101% | +$548K | ﹤0.01% | 7016 |
|
|
2025
Q3 | $552K | Buy |
+10,000
| New | +$520K | ﹤0.01% | 8890 |
|
|
2025
Q2 | – | Sell |
-3,300
| Closed | -$131K | – | 14203 |
|
|
2025
Q1 | $131K | Buy |
3,300
+1,400
| +74% | +$62K | ﹤0.01% | 11080 |
|
|
2024
Q4 | $77.4K | Sell |
1,900
-200
| -10% | -$8.33K | ﹤0.01% | 11825 |
|
|
2024
Q3 | $81.9K | Sell |
2,100
-4,100
| -66% | -$163K | ﹤0.01% | 11381 |
|
|
2024
Q2 | $271K | Sell |
6,200
-6,800
| -52% | -$329K | ﹤0.01% | 9338 |
|
|
2024
Q1 | $620K | Buy |
13,000
+4,200
| +48% | +$189K | ﹤0.01% | 7918 |
|
|
2023
Q4 | $416K | Sell |
8,800
-6,900
| -44% | -$287K | ﹤0.01% | 8487 |
|
|
2023
Q3 | $747K | Buy |
15,700
+5,700
| +57% | +$311K | ﹤0.01% | 7204 |
|
|
2023
Q2 | $582K | Sell |
10,000
-4,600
| -32% | -$276K | ﹤0.01% | 7611 |
|
|
2023
Q1 | $1.04M | Buy |
14,600
+13,000
| +813% | +$1.03M | ﹤0.01% | 6689 |
|
|
2022
Q4 | $113K | Sell |
1,600
-4,100
| -72% | -$289K | ﹤0.01% | 11054 |
|
|
2022
Q3 | $346K | Sell |
5,700
-1,000
| -15% | -$67.1K | ﹤0.01% | 9262 |
|
|
2022
Q2 | $423K | Sell |
6,700
-15,700
| -70% | -$1.02M | ﹤0.01% | 9036 |
|
|
2022
Q1 | $1.44M | Buy |
22,400
+100
| +0.4% | +$6.69K | ﹤0.01% | 6843 |
|
|
2021
Q4 | $1.6M | Sell |
22,300
-16,400
| -42% | -$1.25M | ﹤0.01% | 6736 |
|
|
2021
Q3 | $2.76M | Buy |
38,700
+3,900
| +11% | +$308K | ﹤0.01% | 5561 |
|
|
2021
Q2 | $2.83M | Buy |
34,800
+19,300
| +125% | +$1.55M | ﹤0.01% | 5744 |
|
|
2021
Q1 | $1.17M | Sell |
15,500
-1,000
| -6% | -$72.8K | ﹤0.01% | 7708 |
|
|
2020
Q4 | $1.25M | Sell |
16,500
-7,200
| -30% | -$469K | ﹤0.01% | 6321 |
|
|
2020
Q3 | $1.17M | Sell |
23,700
-4,300
| -15% | -$243K | ﹤0.01% | 5742 |
|
|
2020
Q2 | $1.47M | Buy |
28,000
+19,300
| +222% | +$916K | ﹤0.01% | 5106 |
|
|
2020
Q1 | $306K | Buy |
+8,700
| New | +$508K | ﹤0.01% | 7307 |
|
|
2019
Q4 | – | Sell |
-4,400
| Closed | -$373K | – | 9518 |
|
|
2019
Q3 | $373K | Sell |
4,400
-3,400
| -44% | -$303K | ﹤0.01% | 7239 |
|
|
2019
Q2 | $820K | Buy |
7,800
+2,400
| +44% | +$241K | ﹤0.01% | 6028 |
|
|
2019
Q1 | $570K | Buy |
+5,400
| New | +$542K | ﹤0.01% | 6584 |
|
|
2018
Q4 | – | Sell |
-4,600
| Closed | -$469K | – | 9552 |
|
|
2018
Q3 | $469K | Buy |
+4,600
| New | +$444K | ﹤0.01% | 6803 |
|
|
2017
Q3 | – | Sell |
-4,500
| Closed | -$258K | – | 7854 |
|
|
2017
Q2 | $258K | Buy |
+4,500
| New | +$265K | ﹤0.01% | 6157 |
|
Other funds holding NGVT
VPM
VCM
SBH
SCM
Citadel Advisors's NGVT Position: Q1 2026 in Review
Citadel Advisors reduced its Ingevity (NGVT) stake by 66% in Q1 2026, selling an estimated $1.47M and leaving 10,919 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #8253.
Citadel Advisors first reported a position in NGVT in Q2 2016 and has held it in 32 quarters since. The position peaked at $12.2M in Q2 2020. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.
- Citadel Advisors held 10,919 shares of Ingevity worth $778K as of Q1 2026.
- Citadel Advisors sold 21,534 Ingevity shares in Q1 2026, an estimated $1.47M.
- Ingevity made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8253 holding.
- Citadel Advisors first reported a position in Ingevity in Q2 2016 and has held it in 32 quarters since.
- Citadel Advisors's Ingevity position peaked at $12.2M in Q2 2020.
- 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.